| 摘要 |
PROBLEM TO BE SOLVED: To provide a highly safe anticancer agent resistance-overcoming agent with slight adverse effects. SOLUTION: A compound is represented by formula (I) [wherein, R<SP>1</SP>and R<SP>2</SP>denote each H, an alkyl, an acyl, a cyano or a COOR; R<SP>3</SP>, R<SP>4</SP>, R<SP>13</SP>and R<SP>14</SP>denote each H, an alkyl, an alkoxy, a halogenoalkoxy, an acyl, an acyloxy, hydroxy, a halogen, nitro, cyano, amino or an acylamino; R<SP>5</SP>denotes hydrogen, an alkyl, an alkenyl, an alkynyl or an acyl which may be substituted; R<SP>6</SP>denotes an aroyl or an arylsulfonyl which may be substituted; A, B, G, Q and X denote each N, CH, N→O or N<SP>+</SP>-(R<SP>7</SP>)E<SP>-</SP>(wherein, R<SP>7</SP>denotes an alkyl or an arylalkyl; and E<SP>-</SP>denotes an anion such as a halide ion), except that A, B and G are simultaneously N and A, B, G, Q and X are simultaneously CH; and Y and Z denote each a ring] or its pharmaceutically acceptable salt. An anticancer agent resistance inhibitor comprises the compound represented by formula (I) or its pharmaceutically acceptable salt as an active ingredient. COPYRIGHT: (C)2005,JPO&NCIPI
|
